Cabaletta Doses First Patients with Cellares-Automated CAR-T Therapy
Event summary
- First two patients dosed with Cabaletta's rese-cel therapy manufactured on Cellares' automated Cell Shuttle™ platform (April 2026).
- FDA cleared an Investigational New Drug amendment for Cell Shuttle manufacturing after three years of collaboration.
- Cellares' system aims to reduce manufacturing costs and scale autologous CAR-T production with minimal capital investment.
The big picture
Cellares' automated manufacturing platform addresses long-standing scalability and cost challenges in autologous CAR-T therapy production. The successful dosing of patients with rese-cel marks a critical step toward making these therapies more accessible, particularly as demand grows beyond oncology into autoimmune diseases. The collaboration highlights the industry's shift toward industrialized, high-throughput cell therapy manufacturing.
What we're watching
- Manufacturing Scalability
- Whether Cellares' automated platform can sustainably reduce costs and scale production to meet growing demand for autologous therapies.
- Regulatory Approval
- The pace at which additional regulatory clearances are secured for Cell Shuttle-manufactured therapies beyond rese-cel.
- Market Expansion
- How quickly Cabaletta and other partners adopt the platform to address broader autoimmune disease indications.
Related topics